Congress of PHARMACY in North Macedonia with international participation
Ohrid, 1-4 October, 2026
Pharmacy of the new era - Innovative solutions for future challenges

Global Perspectives on Medical Cannabis Products: Knowledge, Attitudes, Clinical Use, and Safety Perceptions Among Healthcare Professionals and Patients

Mihail Aleksandrov*[1], Marija Pendovska[2]

[1]*Department of Production, Aura Pharm LLC, Koreshnica, 1442 Demir Kapija, Republic of North Macedonia*
[2]*PHI University Clinic for Hematology, Mother Teresa 17, 1000 Skopje, Republic of North Macedonia*

ЈАВНА ЗДРАВСТВЕНА УСТАНОВА Универзитетска Клиника за Хематологија Скопје


BACKGROUND: Medical cannabis and cannabinoid-based medicinal products (CBMPs) are increasingly considered in the management of chronic pain, neurological disorders, epilepsy, oncology-related symptoms and palliative care. However, their safe clinical integration remains influenced by healthcare professionals' knowledge, prescribing confidence, safety perceptions and familiarity with regulatory requirements.

AIM: To synthesize recent evidence on the knowledge, attitudes, clinical use and safety perceptions of medical cannabis among healthcare professionals and patients, and to identify educational, clinical and regulatory barriers to its evidence-based implementation.

METHODOLOGY: A narrative literature review was conducted using peer-reviewed studies published between Jan.2023 and Dec.2025. Cross-sectional surveys, qualitative studies, scoping reviews and international analyses involving healthcare professionals and patients were examined. Findings were synthesized across four domains:

Knowledge and education *Attitudes and acceptance*
Clinical use and confidence *Safety and regulatory perceptions*

KEY FINDINGS



CLINICAL IMPLICATIONS



CONCLUSION: Acceptance of medical cannabis and CBMPs is increasing, but educational, clinical and regulatory gaps continue to limit confident and consistent use. Safe integration into clinical practice requires structured interdisciplinary education, harmonized prescribing guidance, stronger pharmacovigilance and continued high-quality clinical research.

FUTURE PRIORITIES

EDUCATION → CLINICAL GUIDANCE → PHARMACOVIGILANCE → SAFER PATIENT CARE

SCAN FOR FULL SHORT COMMUNICATION

*correspondence: mihail.aleksandrov@aura-pharm.com

References:

Batinic, A. et al., **2024**. *Pharmacy*. 12(1), 2.
Bawa, Z. et al., **2023**. *Int.J.Clin.Pharm*. 45(2), 375–386.
Dassieu, L. et al., **2023.** *Can.J.Pain*. 7(1).
Hareeri, R.H. et al., **2025**. *Medicine*. 104(44), e44900.
Russo, E. et al., **2024**. *J.Cann.Res*. 6, 32.
Sera, L. & Duncan, N., **2023**. *J.Amer.Coll.Clin.Pharm*. 6(7), 732–741.
Syed, S.A. et al., **2025**. *Front.Pub.Health*. 13, 1463871.
Yusupov, E. et al., **2025**. *Med.Cann.&Cannab*. 8(1), 58–64.
Zammit, D.D. et al., **2025**. *Harm.Red.J.* 22, 167.